253 related articles for article (PubMed ID: 23221964)
21. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.
Salman AG; Said AM
Ophthalmic Res; 2015; 53(1):15-20. PubMed ID: 25471087
[TBL] [Abstract][Full Text] [Related]
22. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
23. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
Sukgen EA; Koçluk Y
Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
[TBL] [Abstract][Full Text] [Related]
24. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
Sahinoglu-Keskek N; Akkoyun I; Torer B
Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
[TBL] [Abstract][Full Text] [Related]
25. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
27. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
28. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
29. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
31. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience.
Orozco-Gómez LP; Hernández-Salazar L; Moguel-Ancheita S; Ramírez-Moreno MA; Morales-Cruz MV
Cir Cir; 2011; 79(3):207-214, 225-32. PubMed ID: 22380989
[TBL] [Abstract][Full Text] [Related]
32. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
Sukgen EA; Koçluk Y
Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
34. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
[TBL] [Abstract][Full Text] [Related]
35. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
[TBL] [Abstract][Full Text] [Related]
39. Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia.
Castellanos MA; Schwartz S; Leal R; Chan RV; Quiroz-Mercado H
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):491-4. PubMed ID: 22619071
[TBL] [Abstract][Full Text] [Related]
40. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
Marlow N; Stahl A; Lepore D; Fielder A; Reynolds JD; Zhu Q; Weisberger A; Stiehl DP; Fleck B;
Lancet Child Adolesc Health; 2021 Oct; 5(10):698-707. PubMed ID: 34391532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]